Detail of "20980-22-7"

CAS Number:
20980-22-7
Name:
2-(1-Piperazinyl)pyrimidine
Molecular Structure:
Formula:
C₈H₁₂N₄
Molecular Weight:
164.21
Synonyms:
1-(2-Pyrimidyl)piperazine;1-(4-Pyrimidin-2-yl)piperazine;1-PP;2-Piperazinopyrimidine;4-(2-Pyrimidinyl)piperazine;CM 56324H;MJ 13653;N-2-Pyrimidinylpiperazine;
EINECS:
244-135-5
Density:
1.138 g/cm³
Melting Point:
32-34 °C
Boiling Point:
328 °C at 760 mmHg
Flash Point:
152.1 °C
Appearance:
clear yellow liquid after melting
Hazard Symbols:
Xi
Risk Codes:
36/37/38
Safety:
26-36-24/25 Details

Supplier Location
Supplier Location
- China (Mainland)(18)
- India(4)
- Japan(1)
- United States(1)
- Czech Republic(1)
- Germany(1)
- Canada(1)
Business Type
Business Type
- Lab/Research institutions(2)
- Manufacturers(0)
- Trading Company(20)
Certificates
Certificates
- ISO(1)
- Production License (0)

Display：

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Comparative neuropharmacology of buspirone and MJ-13805, a potential antianxiety drug: Comparative neuropharmacology of buspirone and MJ-13805, a potential antianxiety drug. McMillen, B. A.; Mattiace, L. A. (Univ. Texas, Dallas, TX, USA). J. Neural Transm., 57(4), 255-65 (English) 1983. CODEN: JNTMAH. ISSN: 0300-9564. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) In rats, buspirone [36505-84-7] increases dopaminergic (DA) impulse flow and metab., primarily due to inhibition of DA autoreceptors. However, MJ-13805 [83928-66-9] does not block striatal nerve ending DA autroreceptors and slightly increases striatal DA metab. Both drugs potently reverse catalepsy due to either DA receptor blockade or DA depletion, which indicates an effect within the extrapyramidal system efferent from the DA neuron. Amantadine is at least 10-fold less potent than these drugs for reversal of catalepsy. Altered DA neurotransmission may not be important for the antianxiety effect of buspirone, and buspirone should be tested for efficacy in various models of movement disorders. The site and mechanism of action for buspirone and MJ-13805 remain obscure. A metabolite of buspirone, 1-piperazinylpyrimidine [20980-22-7], does not reverse catalepsy, although this drug is known to be active in antianxiety screening tests. Thus, buspirone may have sep. mechanisms of action for redn. of anxiety and reversal of catalepsy.

Compounds and compositions for treating Parkinson's disease, containing: Compounds and compositions for treating Parkinson's disease, containing .beta.-naphthylmethyl piperazinyl derivates. Hill, Harlan F.; Lafferty, John J. (Smithkline Corp., USA). U.S. US 3988457 26 Oct 1976, 5 pp. Division of U.S. 3,919,230. (English). (United States of America). CODEN: USXXAM. CLASS: IC: A61K031-495. NCL: 424250000. APPLICATION: US 74-440431 7 Feb 1974. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 28 I (R = Ph, pyridyl or pyrimidinyl; R1 = H, alkyl, halo, OH or alkoxy) prepd. by condensation of .beta. 2506-41-4 and 61187-11-9 are also in the experiment.-chloromethylnaphthalene (II) [2506-41-4] with piperazine derivs. are formulated into pharmaceuticals for the treatment of Parkinsonism. Thus, II, Na2CO3 and DMF were added to pyrimidinylpiperazine [20980-22-7]. The mixt. was stirred and heated and washed to give .beta.-naphthylmethyl-4-(2-pyrimidinyl)piperazine (III) [57987-78-7]. Capsules were prepd. contg. 50 mg III/capsule with lactose adjuvant. .